15 Costly Medicare Drugs Selected for Next Round of Price Negotiations
Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T
Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
The next 15 drugs chosen for Medicare negotiation
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare
Ozempic tops new Medicare price negotiation list
At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together as a single drug. Eli Lily's GLP-1 competitor Mounjaro/Zepbound doesn't make the list, but that is because it has not been on the market long enough to be up for consideration.
Medicare Price Negotiations Target Diabetes and Weight-loss Drugs
Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut costs for widely used medications, under the Inflation Reduction Act. Companies must decide by February 28 if they'll join negotiations,
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Ozempic, Wegovy and other drugs are among 15 selected for Medicare's price negotiations
Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including Ozempic and Wegovy, the drugs at the center of the weight-loss craze. The Biden administration said the drugs account for $41 billion in annual Medicare spending,
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
The American Journal of Managed Care25d
Top 5 Most-Read COPD Content of 2024
The top 5 most-read chronic obstructive pulmonary disease (COPD) articles of 2024 covered topics such as inhaled medication risks, gabapentinoid use, and the link between high white blood cell ...
EurekAlert!6d
Commonly prescribed medications increase fall risk and related injuries in people with COPD
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing drugs, according to a new study.
News Medical on MSN5d
The impact of fall-risk medications on injuries in COPD patients
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...